Please login to the form below

Not currently logged in
Email:
Password:

generics

This page shows the latest generics news and features for those working in and with pharma, biotech and healthcare.

Teva wins FDA OK for crucial migraine drug

Teva wins FDA OK for crucial migraine drug

order to pay down a very high level of debt stemming from its $39bn acquisition of Allergan’s generics business Actavis in 2015.

Latest news

More from news
Approximately 89 fully matching, plus 1,099 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 6 fully matching, plus 150 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 31 partially matching documents found.

Latest from PMHub

  • What does a future-proof rep look like?

    Gone are the days of generic data presentations - these brand value propositions should only form one part of a much richer process.

  • 5 years on from the Brazilian Generics Drugs Act, is there still an opportunity for branded originator drugs?

    The only key difference today between similares and generic drugs, is that similares always have a commercial or brand, while generics are only referred to by the name of the molecule. ... In fact the term “ similares” in Brazil is typically used

  • Indians scalp cowboys in patent war

    The only losers are the generics companies. This is a rare case of indians winning against cowboys, if that is how you view generic manufacturers. ... claims? You can expect lawyers working for generics manufacturers to vigorously challenge the Allergan

  • Competition from within

    Teva (Israel), CSL (Australia) and Aspen (South Africa) are notable exceptions, with the Indian generic giants Sun and Ranbaxy - which have since merged - the only representation from the ‘ BRIC’ markets (Brazil,

  • Antibiotic Resistance: Alarm bells ring louder than ever

    The mature nature of the market means the majority of drugs are cheap-to-produce generics, which would make it difficult for a new drug to be seen as cost effective”. ... Further, the mature nature of the market means the majority of drugs are

More from PMHub
Approximately 0 fully matching, plus 60 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics